|[June 19, 2017]
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
The securities litigation law firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches of
fiduciary duty and other violations of state law by the Board of
Directors of SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) ("SciClone"
or the "Company") relating to the proposed buyout of SciClone by a
consortium consisting of entities affiliated with GL Capital Management
GP Limited, Bank of China Group Investment Limited, CDH Investments,
Ascendent (News - Alert) Capital Partners and Boying.
Under the terms of the agreement, SciClone shareholders are anticipated
to receive $11.18 in cash for each share of SciClone common stock held.
The firm's investigation seeks to determine, among other things, whether
the Company's Board of Directors failed to satisfy their duties to
sharehoders, including whether the Board adequately pursued
alternatives to the acquisition and whether the Board obtained the best
price possible for the Company's shares of common stock.
If you currently own common stock of SciClone and believe that the
proposed buyout price is too low, and you would like to learn more about
the investigation being conducted by Brower Piven, please visit our
website at http://www.browerpiven.com/currentinvestigations.html.
You may also request more information by contacting Brower Piven either
by email at email@example.com
or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating
securities and other class action cases and have been advocating for the
rights of shareholders since the 1980s.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170619006166/en/
[ Back To HTML5's Homepage ]